All News
2025 update of EULAR recommendations on lupus nephritis
At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e.
Read Article
Efficacy and Safety of Xeligekimab in AS
Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain
https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI
Dr. John Cush RheumNow ( View Tweet)
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time?
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay decreased over time
🔹️Same trends across world regions & across Human Development Index categories
POS0908 #EULAR2025
@RheumNow https://t.co/Y9gxQDV9KJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis
Presented by Dr Helena Marzo-Ortega at #EULAR2025
@RheumNow https://t.co/3LsJvSiXJV
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Sometimes you hear:
“PMR dose steroids don’t really matter”
Errrrr…
(You wouldn’t accept this steroid exposure in any other disease. Never)
#EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj
David Liew drdavidliew ( View Tweet)
The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome
#EULAR2025 @RheumNow https://t.co/X6VjcN8XZe
Links:
David Liew drdavidliew ( View Tweet)
@RheumNow EULAR haemochromatosis arthropathy classification criteria
Patrick Kiely: please photograph this and take it back to your communities
Patient association lead comes to the microphone, and thanks them for making be seen. 🥲
#EULAR2025 @RheumNow https://t.co/9bqdV0fuPk
David Liew drdavidliew ( View Tweet)
#WIN in systemic sclerosis (SSc):
-Ongoing trials now targeting multiple pathways.
-CONQUEST platform may reshape research in Ssc and other autoimmune diseases.
-Revised CRISS could replace single organ endpoints for approval.
#EULAR2025
@RheumNow https://t.co/kxSeFb5lAU
Links:
Adela Castro AdelaCastro222 ( View Tweet)
+RCT in #pSjD #Sjogrens #Disease
#Leflunomide + #hydroxychloroquine
Vs #PBO
2nd study to show this - same group
need to know
▶️what pt to use this in
▶️is there diff organ improvements
⬆️#ESSDAI
⬇️RF ⬇️Ig’s
Easy to prescribe
?early, mild dx
#EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR vs #ACR #RA #recommendations
Do you agree that #ERA pts should receive #glucocorticoids
@RheumNow #EULAR2025
@eular_org
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ARIAA study: longer-term data now
High-risk ACPA+ clinically suspect arthralgias
abatacept for 6mo, then stop altogether
Really impressive long-term effect
also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while
#EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO
Links:
David Liew drdavidliew ( View Tweet)
Highlights @eular_org #EULAR2025
RCTs + in CTD/RA #ILD w #PPF LB0003
Lots of #CAR-T studies in #SARDs
Lots of bDMARDs in
#SLE
#APS
#IgG4
#SjD
Neurostimulation 👇
⬇️inflammation
⬇️pain
#RA
#fibromyalgia
#EULAR2025 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
EULAR FMF recommendations 2025:
still emphasis on colchicine adherence to maximal dose
+/- bDMARDs if needed for control
+/- csDMARDs for residual chronic MSK involvement
new: consider tapering bDMARD if remission >6mo
See the treatment algorithm below⬇️
#EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL
Links:
David Liew drdavidliew ( View Tweet)
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease.
Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome
⬇️ see the next tweet
#EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx
Links:
David Liew drdavidliew ( View Tweet)
FMF #Recommendations
During attack:
🔺️No use of increasing Colchicine
🔺️No use for corticosteroids and opioid
🔺️Use NSAIDs
#EULAR2025
@RheumNow https://t.co/jJjWJra7yr
Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome
🔺️Do not apply if patient is positive for other antibodies like SSA
#EULAR2025
@RheumNow https://t.co/AD5tTipBtt
Nelly ZIADE 🍀 Nellziade ( View Tweet)
FMF #Recommendations
#Colchicine can be fatal
🔺️Monitor regularly
#EULAR2025
@RheumNow https://t.co/VJZYPaBrvE
Nelly ZIADE 🍀 Nellziade ( View Tweet)
